HIV-preventing PrEP drugs to be offered free in U.S. under ‘deal’

Maricruz Casares
May 13, 2019

The treatment in question is a so-called PrEP drug called Truvada and, if actually enacted, could equate to several million bottles being given out to uninsured patients at high risk of contracting HIV.

Trump tweeted Thursday evening: "Great news today: My Administration just secured a historic donation of HIV prevention drugs from Gilead to help expand access to PrEP for the uninsured and those at risk". According to the article, the study looked at multiple databases in which outpatient drug use information for medications covered by state Medicaid agencies is recorded, as well as opioid mortality figures from the National Center for Health Statistics System for 2005 to 2016. The drug is also used in combination with others in the treatment of HIV-positive people.

The Trump administration has set a objective of ending the HIV outbreak in the USA over a decade.

As part of his anti-HIV drive, the President said his administration needed $291 million to fund efforts during the first year of implementation alone.

More news: Supreme Court rules against Apple in lawsuit targeting App Store

Health and Human Services Secretary Alex M. Azar this week announced a deal for drugmaker Gilead Sciences to donate billions of dollars in HIV drugs to help prevent spread of the disease.

HIV-preventing PrEP drugs will be made available for free to 200,000 people in the United States, it has been announced.

"The majority of Americans who are at risk and who could protect themselves with PrEP are still not receiving the medication". It has been shown to reduce the risk of new infection by up to 97 percent when taken consistently. The drug, despite being manufactured at a relatively low price, can cost a user up to $2,000 for one month's supply.

Following Gilead's announcement, HHS Sec. There are about 1.1 million people in the USA who fall into the at-risk population. Worldwide, there were about 1.8 million new cases of HIV in 2017.

Otros informes por

Discuta este artículo

SIGUE NUESTRO PERIÓDICO